Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines

British Journal of Cancer

Volumn 94, Issue 6, 2006, Pages 914-921

  Terasawa, K ^a   Toyota, M ^a,b,d   Sagae, S ^a   Ogi, K ^a   Suzuki, H ^c   Sonoda, T ^c   Akino, K ^a   Maruyama, R ^a   Nishikawa, N ^a   Imai, K ^a   Shinomura, Y ^a   Saito, T ^a   Tokino, T ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c Department of Public Health ^*  (Japan)

^d Sapporo Medical University   (Japan)

Author keywords

Epigenetics; Methylation; Ovarian cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HEPATOCYTE NUCLEAR FACTOR 1BETA; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; METHYLTRANSFERASE INHIBITOR; TRANSCRIPTION FACTOR; TRICHOSTATIN A;

ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL CANCER; CONTROLLED STUDY; DEACETYLATION; EPIGENETICS; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; GENE TARGETING; HNF4ALPHA GENE; HUMAN; HUMAN CELL; METHYLATION; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; STOMACH CANCER;

BASE SEQUENCE; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION PROFILING; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 33645312660     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602984     Document Type: Article

References (46)

1. Akiyama Y, Watkins N, Suzuki H, Jair KW, van Engeland M, Esteller M, Sakai H, Ren CY, Yuasa Y, Herman JG, Baylin SB (2003) GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol 23: 8429-8439
2. Balch C, Huang TH, Brown R, Nephew KP (2004) The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191: 1552-1572
3. Bellanne-Chantelot C, Chauveau D, Gautier JF, Dubois-Laforgue D, Clauin S, Beaufils S, Wilhelm JM, Boitard C, Noel LH, Velho G, Timsit J (2004) Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med 140: 510-517
4. Bluteau O, Jeannot E, Bioulac-Sage P, Marques JM, Blanc JF, Bui H, Beaudoin JC, Franco D, Balabaud C, Laurent-Puig P, Zucman-Rossi J (2002) Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 32: 312-315
5. Cereghini S, Raymondjean M, Carranca AG, Herbomel P, Yaniv M (1987) Factors involved in control of tissue-specific expression of albumin gene. Cell 50: 627-638
6. Chan MW, Wei SH, Wen P, Wang Z, Matei DE, Liu JC, Liyanarachchi S, Brown R, Nephew KP, Yan PS, Huang TH (2005) Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res 11: 7376-7383
7. Clark SJ, Harrison J, Paul CL, Frommer M (1994) High sensitivity mapping of methylated cytosines. Nucleic Acids Res 22: 2990-2997
8. Costello JF (2005) Comparative epigenomics of leukemia. Nat Genet 37: 211-212
9. Courtois G, Morgan JG, Campbell LA, Fourel G, Crabtree GR (1987) Interaction of a liver-specific nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters. Science 238: 688-692
10. Frain M, Swart G, Monaci P, Nicosia A, Stampfli S, Frank R, Cortese R (1989) The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. Cell 59: 145-157
11. Haumaitre C, Barbacci E, Jenny M, Ott MO, Gradwohl G, Cereghini S (2005) Lack of TCF2/vHNF1 in mice leads to pancreas agenesis. Proc Natl Acad Sci USA 102: 1490-1495
12. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, Lindner T, Yamagata K, Ogata M, Tomonaga O, Kuroki H, Kasahara T, Iwamoto Y, Bell GI (1997) Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 17: 384-385
13. Ishioka S, Sagae S, Terasawa K, Sugimura M, Nishioka Y, Tsukada K, Kudo R (2003) Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system. Gynecol Oncol 89: 447-452
14. Ishiwata I, Ishiguro T, Ishiwata C, Soma M, Ishikawa H (1986) Establishment and characterization of a human ovarian endodermal sinus tumor cell line - producing specific type of alpha-fetoprotein subfraction. Gynecol Oncol 25: 281-293
15. Issa JP (2004) CpG island methylator phenotype in cancer. Nat Rev Cancer 4: 988-993
16. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428
17. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Verma M, Ebina Y, Nomura E, Yamamoto R, Sakuragi N, Dahiya R (2004) Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 316: 1156-1162
18. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi N, Enokida H, Verma M, Dahiya R (2005) WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 104: 1924-1930
19. Kikuchi Y, Miyauchi M, Kizawa I, Oomori K, Kato K (1986) Establishment of a cisplatin-resistant human ovarian cancer cell line. J Natl Cancer Inst 77: 1181-1185
20. Kondo Y, Shen L, Yan PS, Huang TH, Issa JP (2004) Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci USA 101: 7398-7403
21. Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266
22. Laurent-Puig P, Plomteux O, Bluteau O, Zinzindohoue F, Jeannot E, Dahan K, Kartheuser A, Chapusot C, Cugnenc PH, Zucman-Rossi J (2003) Frequent mutations of hepatocyte nuclear factor 1 in colorectal cancer with microsatellite instability. Gastroenterology 124: 1311-1314
23. Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, Fleishman DI, Engelhardt NV, Duncan SA (2004) Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 39: 1038-1047
24. Lemm I, Lingott A, Pogge v Strandmann E, Zoidl C, Bulman MP, Hattersley AT, Schulz WA, Ebert T, Ryffel GU (1999) Loss of HNF1alpha function in human renal cell carcinoma: frequent mutations in the VHL gene but not the HNF1alpha gene. Mol Carcinogen 24: 305-314
25. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH, Davuluri RV, Plass C, Nephew KP, Huang TH (2004) Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 64: 8184-8192
26. Obata T, Toyota M, Satoh A, Sasaki Y, Ogi K, Akino K, Suzuki H, Murai M, Kikuchi T, Mita H, Itoh F, Issa JP, Tokino T, Imai K (2003) Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clin Cancer Res 9: 6410-6418
27. Osanai M, Chiba H, Kojima T, Fujibe M, Kuwahara K, Kimura H, Satoh M, Sawada N (2002) Hepatocyte nuclear factor (HNF)-4alpha induces expression of endothelial Fas ligand (FasL) to prevent cancer cell transmigration: a novel defense mechanism of endothelium against cancer metastasis. Jpn J Cancer Res 93: 532-541
28. Palmisano WA, Crume KP, Grimes MJ, Winters SA, Toyota M, Esteller M, Joste N, Baylin SB, Belinsky SA (2003) Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers. Cancer Res 63: 4620-4625
29. Rebouissou S, Rosty C, Lecuru F, Boisselier S, Bui H, Le Frere-Belfa MA, Sastre X, Laurent-Puig P, Zucman-Rossi J (2004) Mutation of TCF1 encoding hepatocyte nuclear factor 1alpha in gynecological cancer. Oncogene 23: 7588-7592
30. Rebouissou S, Vasiliu V, Thomas C, Bellanne-Chantelot C, Bui H, Chretien Y, Timsit J, Rosty C, Laurent-Puig P, Chauveau D, Zucman-Rossi J (2005) Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Hum Mol Genet 14: 603-614
31. Rey-Campos J, Chouard T, Yaniv M, Cereghini S (1991) vHNF1 is a homeoprotein that activates transcription and forms heterodimers with HNF1. EMBO J 10: 1445-1457
32. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589
33. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141-149
34. Takada T, Yagi Y, Maekita T, Imura M, Nakagawa S, Tsao SW, Miyamoto K, Yoshino O, Yasugi T, Taketani Y, Ushijima T (2004) Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci 95: 741-744
35. Tanaka T, Tomaru Y, Nomura Y, Miura H, Suzuki M, Hayashizaki Y (2004) Comprehensive search for HNF-1beta-regulated genes in mouse hepatoma cells perturbed by transcription regulatory factor-targeted RNAi. Nucleic Acids Res 32: 2740-2750
36. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65: 8961-8967
37. Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A, Mita H, Imai K, Tokino T, Kudo R (2004) Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 10: 2000-2006
38. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB, Issa JP (1999) Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 59: 2307-2312
39. Ueda M, Ueki M, Yamada T, Okamoto Y, Maeda T, Sugimoto O, Otsuki Y (1989) Scatchard analysis of EGF receptor and effects of EGF on growth and TA-4 production of newly established uterine cervical cancer cell line (OMC-1). Hum Cell 2: 401-410
40. Ueki T, Toyota M, Skinner H, Walter KM, Yeo CJ, Issa JP, Hruban RH, Goggins M (2001) Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res 61: 8540-8546
41. Ueno M, Toyota M, Akino K, Suzuki H, Kusano M, Satoh A, Mita H, Sasaki Y, Nojima M, Yanagihara K, Hinoda Y, Tokino T, Imai K (2004) Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol 25: 134-140
42. Xiong Z, Laird PW (1997) COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534
43. Yamada Y, Toyota M, Hirokawa Y, Suzuki H, Takagi A, Matsuzaki T, Sugimura Y, Yatani R, Shiraishi T, Watanabe M (2004) Identification of differentially methylated CpG islands in prostate cancer. Int J Cancer 112: 840-845
44. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd J, Caligiuri MA, Plass C (2005) Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 37: 265-274
45. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast Jr RC (1999) NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 96: 214-219
46. Zardo G, Tiirikainen MI, Hong C, Misra A, Feuerstein BG, Volik S, Collins CC, Lamborn KR, Bollen A, Pinkel D, Albertson DG, Costello JF (2002) Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat Genet 32: 453-458